General information
Immagina Biotechnology unveils DOORs 2.0: a revolution in molecular diagnostics
Immagina Biotechnology Srl proudly announces the completion of the DOORs 2.0 (Detection Of phOspho Rna fragmentS) project, a revolutionary technological platform for the study of biomarkers based on circulating RNA fragments (cfRNA).
These fragments, released into the bloodstream by diseased cells, were until now largely 'invisible' to scientific research. In contrast to the analysis of circulating DNA, the RNA-based approach represents a globally unexplored frontier, in which Imagine has positioned itself at the forefront.
The DOORs 2.0 platform, developed through intensive research, innovation and international collaborations, is able to identify and monitor these RNA fragments.
The technology is already protected by patents and represents valuable intellectual property.
Applications and clinical impact
The technology has been successfully tested on clinical samples of patients suffering from various diseases, including neurodegenerative diseases and skin cancer. The results have enabled the identification of panels of RNA fragments that can act as molecular markers to
- support diagnosis in a more precise and less invasive way;
- monitor disease progression;
- assess response to treatments.
The project has already caught the attention of clinicians and multinationals in the industry, who have started pilot tests to explore the application of this technology in specific clinical cases.
With DOORs 2.0, Imagine Biotechnology expands its technology offering for academia, biotechnology and pharmaceutical companies worldwide, laying the foundation for new opportunities in precision medicine, clinical research and RNA-based drug development. The ultimate goal is to improve patient health and foster important new industrial collaborations.
Start date
01/12/2022
End date
01/12/2024